Safety, Immunogenicity, and Transmissibility of Single-Dose Live Oral Cholera Vaccine Strain CVD l03-HgR in 24- to 59-Month-Old Indonesian Children

Journal of Infectious Diseases

Volumn 168, Issue 5, 1993, Pages 1169-1176

  Levine, Myron M ^a,b,c,d,e   Simanjuntak, Cyrus H ^a,b,c,d,e   O’Hanley, Peter ^a,b,c,d,e   Punjabi, Narain H ^a,b,c,d,e   Noriega, Fernando ^a,b,c,d,e   Pazzaglia, Gary ^a,b,c,d,e   Dykstra, Patricia ^a,b,c,d,e   Kay, Bradford ^a,b,c,d,e   Suharyono, ^a,b,c,d,e   Budiarso, Aswitha ^a,b,c,d,e   Rifai, Atti R ^a,b,c,d,e   Wasserman, Steven S ^a,b,c,d,e   Losonsky, Genevieve ^a,b,c,d,e   Kaper, James ^a,b,c,d,e   Cryz, Stanley ^a,b,c,d,e  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b RSPI Sulianti Saroso   (Indonesia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; PLACEBO;

ABDOMINAL CRAMP; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHOLERA; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEVER; HUMAN; IMMUNOGENICITY; INDONESIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEROCONVERSION; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; FECES; HUMAN; IMMUNOGLOBULIN G; INDONESIA; SAFETY; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; URBAN POPULATION; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0027372938     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/168.5.1169     Document Type: Article

References (56)

1. Swerdlow OJ, Mintz ED, Rodriguez M, Waterborne transmission of epidemic cholera in Trujillo, Peru: Lessons for a continent at risk, Lancet 1992; 340: 28-33.
2. Levine MM, Pierce NF, Immunity and vaccine development, In: Greenough WBIII, Barua D, eds, Cholera, New York: Plenum Press, 1992: 285-327.
3. Feeley JC, Gangarosa EJ, Field trials of cholera vaccine, In: Cholera and related diarrhoeas, 43rd Nobel Symposium, Stockholm, 1978, Basel: Karger, 1980: 204-10.
4. Glass RI, Claeson M, Blake PA, Waldman RJ, Pierce NF, Cholera in Africa: Lessons on transmission and control for Latin America, lancet 1991; 338: 791-5.
5. World Health Organization, Guidelines for cholera control, Geneva: WHO, 1991; WHO/CDD/SER/80A, rev 2.
6. Diarrhoeal Diseases Control Programme, World Health Organization, Biomedical and epidemiological research priorities of global scientific working groups, Geneva: WHO, 1987; WHO/CDD/SER/86, 8, rev I.
7. Levine MM, Vaccines against enteric infections, Lancet 1990; 335: 958-61.
8. Levine MM, Kaper JB, Live vaccines against cholera: An up-date, Vaccine 1993; II: 207-12.
9. Clemens JD, Harris JR, Sack DA, Field trial of oral cholera vaccines in Bangladesh: Results of one year of follow-up, J Infect Dis 1988; 158: 60-9.
10. Clemens JD, Sack DA, Harris JR, Field trial of oral cholera vaccines in Bangladesh: Results from three year follow-up, Lancet 1990; 335: 270-3.
11. Kaper JR, Lockman H, Baldini MM, Levine MM, Recombinant live oral cholera vaccine, Biotechnology 1984; 2: 345-9.
12. Mekalanos JJ, Swartz SJ, Pearson GDN, Cholera toxin genes: Nucleotide sequence, deletion analysis, and vaccine development, Nature 1983; 306: 551-7.
13. Kaper JR Levine MM, Recombinant attenuated Vibrio cholerae strains used as live oral vaccines, Res Microbiol 1990; 141: 901-6.
14. Levine MM, Kaper JB, Herrington O, Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccine CVD 103 and CVD 103-HgR, Lancet 1988; 2: 467-70.
15. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB, Construction of genetically-marked Vibrio cholerae 0 I vaccine strains, FEMS Microbiol Lett 1993 (in press).
16. Cryz SC, Levine MM, Kaper J B, Furer E, Althaus B, Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults, Vaccine 1990; 8: 577-80.
17. Kotloff K, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM, Safety and immunogenicity in North Americans ofa single dose oflive oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind cross-over trial, Infect Immun 1992; 60: 4430-2.
18. Cryz S, Levine MM, Losonsky G, Kaper JB, Althaus 8, Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults, Infect Immun 1992; 60: 3916-7.
19. Tacket CO, Losonsky G, Nataro J, Rapid onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR, J Infect Dis 1992; 166: 83741.
20. Migasena S, Pitisuttitham P, Prayurahong B, Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults, Infect Immun 1989; 57: 3261-4.
21. Su-Arehawatana P, Singharaj P, Taylor O, Safety and immunogenicity of different immunization regimens ofCVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand, J Infect Dis 1992; 165: 1042-8.
22. Suharyono, Simanjuntak C, Witham N, Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9year- old Indonesian children, Lancet 1992; 340: 689-94.
23. Gotuzzo E, Penny M, Seas C, The safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine, CVD 103hgR in Peruvian adults of high and low socioeconomic level, Infect Immun 1993 (in press).
24. Simanjuntak CH, Hasibuan MA, Siegar LO, Koiman I, Etiologi mikrobiologis penyakit diare akut, Health Studies Indonesia 1983; II: 1-9.
25. Simanjuntak CH, Harjining S, Hasibuan MA, Pujarwoto, Koiman I, Laboratory aspects of gastrointestinal infections in Indonesia: 1980-1985, In: Proceedings ofthe 14th SEAMIC Workshop, Gastrointestinal Infections in Southeast Asia, Tokyo: SEAMIC, 1988: 23-31.
26. Clemens JD, Stanton BF, Chakraborty J, B subunit-whole cell and whole cell-only oral vaccines against cholera: Studies on reactogenicity and immunogenicity, J Infect Dis 1987; 155: 79-85.
27. Farmer JJ, Hickman-Brenner FW, Kelly MT, Vibrio, In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy J, eds, Manual of clinical Microbiology, 4th ed, Washington, DC: American Society for Microbiology, 1985: 282-301.
28. Lesmana M, Rockhill RC, A CAMP phenomenon between V, cholerae biotype EI Tor and staphylococcal, a-hemolysin, Southeast Asian J Trop Med Public Health 1985; 16: 261-4.
29. Barrett TJ, Blake PA, Morris GK, Puhr NO, Bradford HR, Wells lG, Use of Moore swabs for isolating Vibrio cholerae from sewage, J Clin Microbiol 1980; II: 385-8.
30. Sears SO, Ferreccio C, Levine MM, Sensitivity of Moore sewer swabs for isolating Salmonella typhi, Appl Environ Microbiol 1986; 51: 425-6.
31. Benenson AS, Saad A, Mosley WH. Serological studies in cholera, 2, The vibriocidal antibody response ofcholera patients determined by a microtechnique, Bull WHO 1968; 38: 277-85.
32. Clements ML, Levine MM, Young CR, Magnitude, kinetics and duration of vibriocidal responses in North Americans following ingestion of Vibrio cholerae, J Infect Dis 1982; 145: 465-73.
33. Levine MM, Young CR, Black RE, Takeda Y, Finkelstein RA, Enzyme- linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: Application in serodiagnosis and seroepidemiology, J Clin Microbiol 1985; 21: 174-9.
34. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA, Volunteer studies in development ofvaccines against cholera and enterotoxigenic Escherichia coli: A review, In: Holme T, Holmgren J, eds, Acute enteric infections in children: New prospects for treatment and prevention, Amsterdam: Elsevier, 1981: 443-59.
35. Mosley WH, Beneson AS, Barui R, A serological survey for cholera antibodies in rural east Pakistan, I, The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titer to the pattern of endemic cholera, Bull WHO 1968; 38: 327-34.
36. Mosley WH, Ahmad S, Benenson AS, Ahmed A, The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients, Bull WHO 1968; 38: 777-85.
37. Glass RL, Svennerholm AM, Khan MR, Huda S, Huq ML Holmgren J, Seroepidemiological studies ofEI Tor cholera in Bangladesh: Association of serum antibody levels with protection, J Infect Dis 1985; 151: 236-42.
38. Clements JD, Van Loon F, Sack DA, Field trial of oral cholera vaccines in Bangladesh: Serum vibriocidal and antitoxic antibodies as markers of the risk of cholera, J Infect Dis 1991; 163: 1235-42.
39. Weissman ra Gangarosa EJ, Schmerler A, Marier RL, Lewis IN, Shigellosis in day-care centers, Lancet 1975; 1: 88-90.
40. Pickering LK, Bartlett AV, Woodward WE, Acute infectious diarrhea among children in daycare: Epidemiology and control, Rev Infect Dis 1986; 8: 539-47.
41. Clemens JD, Sack DA, Harris JR, Field trial of oral cholera vaccines in Bangladesh, Lancet 1986; 2: 124-7.
42. Mosley WH, McCormack WM, Ahmed A, Report ofthe 1966-67 cholera vaccine field trial in rural East Pakistan, I, Study design and results of the first year of observation, Bull WHO 1969; 40: 177-85.
43. Philippines Cholera Committee, A controlled field trial of the effectiveness of cholera and cholera EI Tor vaccines in the Philippines, Bull WHO 1965; 32: 603-25.
44. Saroso JS, Bahrawi W, Witjaksono H, A controlled field trial of plain and aluminum hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973-75, Bull WHO 1978; 56: 619-27.
45. Das Gupta A, Sinha R, Shrivastava DL, Controlled field trial ofthe effectiveness of cholera and cholera EI Tor vaccines in Calcutta, Bull WHO 1967; 37: 371-85.
46. Sabin AB, Oral poliomyelitis vaccine, History of its development and prospects for eradication of poliomyelitis, JAMA 1965; 194: 130-4.
47. Woodrow G, An overview ofbiotechnology as applied to vaccine development, In: Woodrow G, Levine MM, eds, New generation vaccines, New York: Marcel Dekker, 1990: 31-42.
48. Fox JL, Anticipating deliberate release, A growing intellectual industry, ASM News 1985; 51: 619-20.
49. Fox JL, Contemplating suicide genes in the environment, Conditional lethal mutations may minimize risk when engineered microbes are released into the environment, ASM News 1989; 55: 259-61.
50. Fox JL, Rabies vaccine field test-pending, An engineered vaccine for use on wild animals seems ready for testing, but state health officials and environmentalists are seeking delays, ASM News 1989; 55: 355-7.
51. Current Topics, NIH RAC eases deliberate release restrictions, ASM News 1987; 53: 195-6.
52. Tieder JM, Colwell RK, Grossman YL, The planned introduction of genetically-engineered organisms: Ecological considerations and recommendations, Ecology 1989; 70: 298-316.
53. Moore B, Perry EL, Chard ST, A survey by the sewage swab method of latent enteric infections in an urban area, J Hyg 1952; 50: 137-56.
54. Sears SO, Ferreccio C, Levine MM, The use of Moore swabs for isolation ofSalmonella typhi from irrigation water in Santiago, Chile, J Infect Dis 1984; 149: 640-2.
55. Robbins A, Freeman P, The Children's Vaccine Initiative, Lancet 1991; 338: 1006-7.
56. Viret J, Cryz S, Lang A, Favre D, Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains, Mol Microbiol 1993; 7: 239-52.